Target intelligence / Profile preview

Novel transcript, antisense to TSC22D3 (ENSG00000294438)

Target: ENSG00000294438
Molecular classification: Other (uncharacterized noncoding RNA, antisense transcript)

Overview

The "novel transcript, antisense to TSC22D3" (ENSG00000294438) is a genome-annotated, uncharacterized antisense RNA located opposite the well-described TSC22D3 gene. There is currently no experimental or clinical information concerning its expression, function, disease relevance, pharmacology, or biomarker status. This transcript is not recognized as a therapeutic target in drug development or biology, and is referenced primarily in the context of genome annotation databases. For clinical, therapeutic, and molecular insights, information should refer to the protein-coding gene TSC22D3 (Glucocorticoid-induced leucine zipper, GILZ).

Beyond the preview

Go deeper on Novel transcript, antisense to TSC22D3 (ENSG00000294438).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to TSC22D3 (ENSG00000294438).

Explore the full profile